Replies to post #348739 on Option Millionaires

[uranium-pinto-beans]

Pfizer CEO Albert Bourla CNBC interview: He has a "very high degree of confidence" that Paxlovid (COVID-19 antiviral) will be effective because it doesn't target the spike proteins; if vaccine effectiveness drops, PFE can make new vaccine in 95 days (54.00)
Mr. Bourla said:

He expects company can produce 80 mln courses of Paxlovid (COVID-19 antiviral) versus previous estimate of 50 mln doses.
He has a "very high degree of confidence" that Paxlovid will effective because it doesn't target the spike proteins.
There are a lot of unknowns about Omicron; he thinks information will be known within weeks.
He is concerned about Omicron variant, but he has been preparing for it.
Paxlovid was designed for potential mutations in mind.
Third dose of vaccine provides very high protection against Delta variant.
Unclear if effectiveness will be reduced and by how much with Omicron variant.
He made a new template to for new vaccine if needed.
If the effectiveness drops to a low level, Pfizer can make new vaccine in 95 days.